Pimavanserin is primarily used in the treatment of Parkinson’s disease psychosis (PDP), a condition where individuals experience hallucinations and delusions. It works as a selective serotonin inverse agonist, specifically targeting serotonin 5-HT2A receptors, which helps reduce psychotic symptoms without worsening motor function. This makes it a valuable option for patients with Parkinson’s, as it avoids the side effects associated with traditional antipsychotics. Additionally, it has been explored for potential use in other psychiatric conditions, such as Alzheimer’s disease-related psychosis and major depressive disorder, though these applications are still under investigation. Its unique mechanism of action offers a targeted approach to managing psychosis in vulnerable patient populations.